AbbVie's Dual Regimen Receives EC's Approval for Patients with Previously Untreated Chronic Lymphocytic Leukemia
Shots:
- The approval is based on P-III CLL14 study assessing Venclyxto (venetoclax) + obinutuzumab vs obinutuzumab + chlorambucil in 432 patients with previously untreated CLL and coexisting medical condition
- The P-III CLL14 study results: median follow up @28mos. superior PFS; @40mos. median PFS had not been reached (35.6mos.); @36mos. PFS (81.9% vs 49.5%) @1yr. patients experienced deep response as measured by higher rates of undetectable MRD or CR
- Venclyxto is a first-in-class therapy targeting BCL-2 protein and works to restore the process of apoptosis and has received a CHMP’s positive opinion for MAA in combination with obinutuzumab to treat CLL in Jan’2020
Click here to read full press release/ article
Ref: AbbVie | Image: abbvie
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com